title: Histopathological Evaluation of the Effects of CAPE in Experimental Spinal Cord Injury.
abstract: OBJECTIVE
  < /B > Spinal cord injuries negatively affect the individuals and the life quality of their families due to neurological deficits caused by trauma. The prevalence of spinal cord injury is 15-45/1 million in the world. Caffeic acid phenethyl ester (CAPE) is the most active component of propolis and has neuroprotective, anti-oxidant and anti-apoptotic effects. Our aim was to determine the effects of CAPE on the prevention of secondary injury and to compare with methylprednisolone.
  
  
  METHODS
  Forty rats were divided into 4 groups. The control group did not undergo surgery (Group I), only trauma group (Group II), trauma+CAPE treatment group (Group III), and trauma+methylprednisolone treatment group (Group IV). Histopathological assessment was performed with two staining methods as hematoxylin-eosin (HE) and terminal deoxynucleotidyl Transferase Biotin - dUTP Nick End Labeling (TUNEL). The groups were statistically compared.
  
  
  RESULTS
  The apoptotic cells decreased in treatment groups compared with the trauma. CAPE has more anti-apoptotic effect than methylprednisolone. The histological difference between the Group II, and Groups III and IV was statistically significant.
  
  
  CONCLUSIONS
  CAPE has a positive effect on spinal cord injuries by preventing apoptosis.
authors.affiliation: Eskisehir State Hospital, Department of Neurosurgery, Eskisehir, Turkey.
authors.forename: Hasan Emre
authors.initials: HE
authors.lastname: Aydin
authors.forename: Emre
authors.initials: E
authors.lastname: Ozkara
authors.forename: Zuhtu
authors.initials: Z
authors.lastname: Ozbek
authors.forename: Murat
authors.initials: M
authors.lastname: Vural
authors.forename: Dilek
authors.initials: D
authors.lastname: Burukoglu
authors.forename: Ali
authors.initials: A
authors.lastname: Arslantas
authors.forename: Metin Ant
authors.initials: MA
authors.lastname: Atasoy
mesh_terms: D000082:Acetaminophen / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002109:Caffeic Acids / Q000627:therapeutic use*; D005260:Female; D020287:In Situ Nick-End Labeling; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013119:Spinal Cord Injuries / Q000188:drug therapy*
chemical_list: D018712:Analgesics, Non-Narcotic; D002109:Caffeic Acids; D018696:Neuroprotective Agents; D000082:Acetaminophen; C055494:caffeic acid phenethyl ester; D010626:Phenylethyl Alcohol; D008775:Methylprednisolone